A 3-week pause versus continued Bruton tyrosine kinase inhibitor use during COVID-19 vaccination in individuals with chronic lymphocytic leukaemia (IMPROVE trial): a randomised, open-label, superiority trial

Authors: Jonathan A Cook, Piers E M Patten, Nicholas Peckham, Paul Moss, Neil Phillips, Abhishek Abhishek, Thomas Roberts, Marie Hodges, Georgina Talbot, Vicki Barber, Anne Francis, Adrian M Shields, Lelia Duley, Robbert Hoogeboom, Brian J Willett, Sam Scott, Nilima Parry-Jones, Toby A Eyre, Gareth Plested, Gratian Vandici, Farooq Ahmad Wandroo, Claire Hutchinson, Shankara Paneesha, Duncan J Murray, Nicolas Martinez-Calle, Stephen Jenkins, Earnest Heartin, Helen M Parry

Published: 2025-04-03

DOI: 10.1016/s2352-3026(25)00008-0

Source: Full article


Abstract

No abstract found.